HC Wainwright & Co. Initiates Coverage On OKYO Pharma with Buy Rating, Announces Price Target of $4
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Yi Chen has initiated coverage on OKYO Pharma (NASDAQ:OKYO) with a Buy rating and a price target of $4.
November 02, 2023 | 11:07 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
OKYO Pharma has been initiated with a Buy rating by HC Wainwright & Co., with a price target of $4.
The initiation of coverage by HC Wainwright & Co. with a Buy rating and a price target of $4 indicates a positive outlook for OKYO Pharma. This could potentially attract investors and drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100